Exagen Showcases Six Scientific Presentations at ACR’s First Virtual Annual Meeting in November 2020
October 21 2020 - 4:05PM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
autoimmune diseases, announced today it will be
presenting new scientific research at the American College of
Rheumatology’s (ACR) first virtual annual meeting, ACR Convergence
2020. The event is being held online from November 5-9, 2020.
Exagen’s Chief Scientific Officer, Anja Kammesheidt, shared,
“Exagen is honored to have had the opportunity to partner with such
great collaborators on this year’s abstracts. Our clinical research
and development teams are committed to advancing the understanding
of the role of cell-bound complement activation products (CB-CAPs)
in lupus. We are pleased to be sharing these data at this year’s
virtual ACR event.”
Below is the list of accepted abstracts along with links to
each:
Saturday, November 7th
Poster Presentation | Presented by Michelle Petri, MD |
Abstract #0857Title: Agreement of Hydroxychloroquine Blood
Levels Between a University and Commercial LaboratorySession Title:
SLE – Treatment Poster ISession Time: 9:00 am – 11:00 am EST
Sunday, November 8th
Oral Presentation | Presented by
Yevgeniya Gartshteyn, MD
| Abstract #1510Title: Platelet-bound C4d is Associated
with Platelet Activation and Arterial Thrombotic EventsSession
Title: SLE – Diagnosis, Manifestations, & Outcomes II: Bench to
Bedside (1507–1511)Session Time: 3:00 pm – 3:50 pm EST
Oral Presentation | Presented by Michelle Petri, MD |
Abstract #1513Title: Role of Platelet C4d in Thrombosis
and Lupus NephritisSession Title: SLE – Diagnosis, Manifestations,
& Outcomes III: Lupus Nephritis (1512–1516)Session Time: 4:00
pm – 4:50 pm EST
Monday, November 9th
Poster Presentation | Presented by
Yevgeniya Gartshteyn, MD
| Abstract #1792Title: Platelet-bound C4d is Associated
with an Increased Risk of Arterial and Venous Thromboses in
SLESession Title: SLE – Diagnosis, Manifestations, & Outcomes
Poster III: Bench to BedsideSession Time: 9:00 am – 11:00 am
EST
Poster Presentation | Presented by
Rosalind Ramsey-Goldman, MD | Abstract
#1797Title: A Multianalyte Assay Panel (MAP) With
Algorithm Containing Cell-Bound Complement Activation Products
(CB-CAPs) Is Superior to Anti-dsDNA And Low Serum Complement Levels
in Predicting Transition of Probable Lupus to ACR Classified Lupus
Within 2 YearsSession Title: SLE – Diagnosis, Manifestations, &
Outcomes Poster III: Bench to BedsideSession Time: 9:00 am – 11:00
am EST
Poster Presentation | Presented by Jill
Buyon, MD | Abstract #1808Title:
Erythrocyte Complement Receptor 1 (ECR1) and Erythrocyte Bound C4d
(EC4d) Associate with Adverse Pregnancy Outcomes and Preeclampsia
in Pregnant Women with Systemic Lupus Erythematosus (SLE)Session
Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III:
Bench to Bedside Session Time: 9:00 am – 11:00 am EST
* Abstracts will remain live until March 11, 2021
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand. Several of these products are based on our
proprietary Cell-Bound Complement Activation Products, or CB-CAPs,
technology. CB-CAPs assess the activation of the complement system,
a biological pathway implicated in systemic lupus erythematosus, or
SLE. Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis, or RA. Exagen’s model of
integrating testing products and therapeutics
positions Exagen to offer targeted solutions to
rheumatologists and, ultimately, better serve patients. For
more information, please visit www.Exagen.com
Forward Looking Statements
Exagen cautions you that statements contained in this press
release regarding matters that are not historical facts are
forward-looking statements. These statements are based on the
company’s current beliefs and expectations. Such forward-looking
statements include, but are not limited to, statements regarding
the scientific abstracts for presentation at ACR Annual Conference
and the potential to lead to increased adoption of any AVISE®
test. The inclusion of forward-looking statements should not
be regarded as a representation by Exagen that any of its
plans will be achieved. Actual results may differ from those set
forth in this press release due to the risks and uncertainties
inherent in Exagen’s business, including, without limitation: the
COVID-19 pandemic may continue to adversely affect our business,
financial condition and results of operations, Exagen’s commercial
success depends upon attaining and maintaining significant market
acceptance of its testing products and promoted therapeutics among
rheumatologists, patients, third-party payers and others in the
medical community; third party payers not providing coverage and
adequate reimbursement for the company’s testing products or
promoted therapeutics; the company’s ability to obtain and maintain
intellectual property protection for its testing products;
regulatory developments affecting the company’s business; risks
associated with maintaining third-party partnerships and Exagen’s
performance thereunder; and other risks described in the company’s
prior press releases and the Company’s filings with
the Securities and Exchange Commission (SEC), including
under the heading “Risk Factors” in the company’s Annual Report on
Form 10-K and any subsequent filings with the SEC. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof,
and Exagen undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date hereof. All forward-looking statements are qualified
in their entirety by this cautionary statement, which is made under
the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995.
InvestorsWestwicke PartnersMike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838
CompanyExagen Inc.Kamal Adawi, Chief Financial
Officerkadawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2023 to Apr 2024